STOCKS TELEGRAPH

Category: Mid Day Movers

  • Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement

    Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement

    Shares of Portage Biotech Inc. (NASDAQ: PRTG) are experiencing upward momentum, rising 4.31% to $4.60 during the pre-market session. This increase follows the announcement of a significant equity transaction. Over the past week, the stock has seen a 5.00% gain. Investors seeking comparable biotechnology stocks with a market capitalization under $200 million and gains exceeding 5% can explore options via our ST screener link.

    Equity Financing and Corporate Utilization

    Portage Biotech has successfully completed a private placement, raising $2.15 million through the sale of 524,390 ordinary shares at $4.10 per share. This transaction, executed at the official Nasdaq closing price on January 22, 2025, was funded by two Portage directors. PRTG intends to utilize the proceeds for working capital and other corporate purposes across its subsidiaries, reinforcing its financial stability and operational expansion.

    Strategic Relaunch of Cyncado Therapeutics

    In a strategic move, Portage Biotech has restructured one of its subsidiaries, relaunching it as an independently managed entity under the name Cyncado Therapeutics Inc. This newly rebranded company will focus on advancing best-in-class adenosine receptor antagonists. As Chief Executive Officer, Peter Molloy, a seasoned professional in the field, will be responsible for obtaining outside funding and spearheading clinical research projects for the subsidiary’s potential medicinal portfolio.

    Immuno-Oncology Advancement Via the Adenosine Pathway Investigate

    The development of A2a and A2b receptor antagonists, which are intended to provide strong, targeted, and long-lasting suppression of immune suppression signals inside the tumor microenvironment, will be led by Cyncado Therapeutics. These treatments aim to completely inhibit immune evasion pathways, which will strengthen the immune system’s capacity to generate a strong anti-tumor response. They are designed to be administered twice to maximize synergy.

    Portage Biotech is still dedicated to increasing shareholder value and realizing the full potential of its assets. The business thinks it can optimize the effects of its adenosine program by making Cyncado a stand-alone firm. Moving forward, Cyncado Therapeutics aims to generate proof-of-concept data, further solidifying the role of its innovative treatments in the evolving landscape of oncology.

  • Nauticus Robotics (KITT) Sees Strong Market Gains Following Key Partnership

    Nauticus Robotics (KITT) Sees Strong Market Gains Following Key Partnership

    Nauticus Robotics, Inc. (NASDAQ: KITT) shares have had a spectacular increase, rising 28.53% to $2.01 as of the most recent market update. This significant rise is a result of the company’s newly disclosed strategic partnership, which is a crucial step in its quest for improvements in subsea autonomy.

    Partnership to Promote Subsea Autonomy

    Leading provider of software and autonomous subsea robots, Nauticus robots, has established a strategic partnership with Leidos (NYSE: LDOS). The two firms’ past successful engagement, which was praised by their joint client for its flawless execution and operational synergy, forms the foundation of this cooperation.

    The goal of the reestablished partnership is to combine their specialized knowledge to create autonomous underwater systems of the future that can handle ever-more-complex subsea tasks. Nauticus Robotics reaffirms its dedication to pushing the limits of technology in subsea autonomy with this prolonged partnership.

    KITT will make use of its cutting-edge commercial subsea vehicle development capabilities, especially with its proprietary unmanned vehicle software platform ToolKITT and flagship Aquanaut system. Future autonomous underwater vehicles should operate much more effectively and efficiently thanks to these technology.

    Strengthening Market Position

    Nauticus Robotics continues to strengthen its market presence within the Aerospace & Defense industry. The company currently holds a “Buy” recommendation at our ST Screener, reflecting its promising growth trajectory. Investors interested in similar high-performing peer stocks can explore a compiled list through our screener link.

    Successful Project Execution in the Gulf of Mexico

    Further expanding its reach, Nauticus Robotics recently completed a high-profile project for a second global supermajor oil and gas company in the Gulf of Mexico. The project involved conducting a subsea field inspection utilizing the advanced Aquanaut Mark 2 underwater vehicle.

    The Autonomous Solutions team successfully executed visual inspections over multiple days, validating the effectiveness of KITT’s technology in meeting the customer’s subsea operational objectives. This collaboration underscores the company’s ability to enhance decision-making while reducing environmental impact.

    By deploying autonomous technology, Nauticus Robotics significantly lowers daily diesel fuel consumption and associated emissions for each operational Aquanaut, reinforcing its commitment to sustainable and efficient subsea exploration.

  • Reborn Coffee (REBN) Shares Rally Amid Expansion Milestone

    Reborn Coffee (REBN) Shares Rally Amid Expansion Milestone

    Reborn Coffee, Inc. (NASDAQ: REBN) shares are surging significantly on the charts today, up 63.30% to $3.32 as of the last check. This rise comes after a significant event that caused REBN stock to soar by more than 62% in a single week, indicating that investors have high faith in the company’s future prospects.

    Approval of the Franchise Opens the Door to Growth

    An important turning point in Reborn Coffee’s expansion plan was reached last week when the company formally obtained its registration as a franchisor in the US. With this clearance, the business has revealed intentions for rapid growth, with the goal of opening more than 100 franchise units around the country in the next three years.

    This action not only solidifies its position in the home market but also creates the framework for future expansion abroad. While aggressively seeking permits in other jurisdictions, Reborn Coffee is currently permitted to operate in California and non-franchise registration states.

    A Strategic Perspective for Sector Leadership

    Reborn Coffee sees its franchise model as a major factor in its success and wants to establish itself as a major force in the specialty coffee market. The brand is reinventing the contemporary coffee experience by combining artisanal baked items with premium coffee and tea offerings.

    Its scalable store designs and innovative brewing techniques set a new standard for specialty coffee establishments, attracting both customers and potential franchise partners. Beyond serving high-quality beverages, REBN is committed to fostering a globally recognized brand that harmonizes quality, innovation, and cultural appreciation.

    A Global Growth Trajectory

    With its franchise approval serving as a catalyst, Reborn Coffee is strategically positioned for sustained expansion. By emphasizing exceptional customer experiences, advanced brewing methods, and thoughtfully curated offerings, the company aims to distinguish itself in both U.S. and emerging global markets.

    More than just a café, each Reborn Coffee location aims to serve as a community and cultural center where patrons may experience a welcoming and cozy environment. REBN’s strategy highlights its goal of becoming a worldwide lifestyle brand by fusing innovation and heritage.

    Meanwhile, REBN stock holds an ‘Undervalued’ rating in the Restaurants industry, as per our ST screener. Investors seeking further insights into similar industry stocks can explore our screener link for comparative analysis.

  • Pre-Market Gains For Viavi Solutions (VIAV) After Earnings Rebound

    Pre-Market Gains For Viavi Solutions (VIAV) After Earnings Rebound

    Viavi Solutions Inc. (NASDAQ: VIAV) shares are seeing a significant 22.01% increase as of the latest premarket check, hitting $12.19. This increase comes after the company’s most recent earnings report, which beat market forecasts.

    Improved Financial Position

    The strong financial outcomes were mostly ascribed to a rebound in demand for Network and Service Enablement (NSE). Viavi’s net sales increased 6.4% year over year (YoY) to $270.8 million. Furthermore, Non-GAAP diluted earnings per share (EPS) increased 18.2% YoY to $0.13, while Non-GAAP net income jumped 24.1% YoY to $29.4 million. These robust financial metrics demonstrate the business’s capacity to seize market opportunities and boost profitability.

    Market Positioning

    Investment analysts have responded favorably, assigning Viavi a “Buy” recommendation. Moreover, it has an ST score of 46 on our screener. Investors interested in exploring similar stocks within the Communication Equipment sector can refer to our ST screener link for further insights.

    Introduction of AI-Powered RAN Scenario Generator

    Further solidifying its technological leadership, Viavi recently unveiled the TeraVM AI RAN Scenario Generator (AI RSG), an advanced evolution of its RAN Intelligent Controller (RIC) Test platform. This innovation enhances simulated system-level RAN behavior, creating a digital twin that accurately replicates real-world network conditions within laboratory environments.

    The AI RSG is particularly relevant for platform and application developers targeting the National Telecommunications and Information Administration (NTIA) Public Wireless Supply Chain Innovation Fund (PWSCIF) Third Notice of Funding Opportunity (NOFO 3). This funding opportunity focuses on software solutions for industry verticals and integration automation, areas where Viavi’s expertise is well-established.

    Advancing Open RAN and AI-Driven Network Optimization

    Utilizing Open RAN interfaces, the AI RSG is designed to train the RIC and r/xApps, enabling improvements in quality of service, industry-specific functionalities, energy efficiency, and network optimization. It is capable of simulating up to 10,000 user equipment (UEs) and thousands of network cells, making it a powerful tool for large-scale network testing and validation.

    As the sole test and optimization vendor to receive PWSCIF funding under NOFO 1 and a key partner in NOFO 2, Viavi has garnered the trust of the NTIA. The company continues to play a critical role in testing, securing, and validating major global communication networks, reinforcing its position as a preferred partner for leveraging AI and machine learning to enhance network performance.

  • Atlassian (TEAM) Stock Climbs In Pre-Market After Positive Earnings

    Atlassian (TEAM) Stock Climbs In Pre-Market After Positive Earnings

    Pre-market activity for Atlassian Corporation (NASDAQ: TEAM) is booming, as seen by the shares’ 19.49% increase to $318.99 as of the most recent check. This increase comes after the market closed yesterday after the release of strong financial results.

    Strong Revenue Growth and Effective Enterprise Sales Management

    Strong enterprise sales across its Cloud and Data Center products propelled Atlassian’s (TEAM) impressive 30% annual growth in subscription revenue. The company reported $1,286.5 million in sales for the second quarter that ended on December 31, 2024, a 21% increase over the $1,060.1 million reported during the same time the previous year. The firm credits its success to the expansion of its System of Work architecture, strategic investments in enterprise services, and artificial intelligence (AI).

    Working Together Strategically to Increase Cloud Capabilities

    By entering into a multi-year strategic collaboration deal with Amazon Web Services (AWS), Atlassian has strengthened its cloud ecosystem even further. This expansion upholds strict security, privacy, and compliance requirements while giving the company clients better access to cloud-enabled services, such as AI-driven tools.

    To assist large-scale business migrations, improve AI-driven solutions, and provide solution partners with cloud expertise, Atlassian and AWS will create a Cloud Center of Excellence as part of this endeavor. Furthermore, TEAM has increased the capacity of Confluence Cloud, enabling smooth data center to cloud migrations by supporting up to 150,000 users on a single site, which is three times the prior maximum.

    Industry Recognition and Market Leadership

    Atlassian’s industry leadership continues to be recognized on multiple fronts. In 2024, the company was named a Leader in The Forrester Wave for Knowledge Management Solutions, Gartner’s Magic Quadrant for Marketing Work Management Platforms, and IDC MarketScape for IT Service Management Software. These accolades highlight the strength of Atlassian’s product suite, including Confluence, Jira, Rovo, and Loom.

    Further solidifying its market standing, Atlassian secured the top spot on Fortune’s Future 50 List for 2024, reflecting its commitment to innovation, adaptability, and delivering value across technology and business sectors. The company concluded the second quarter with 49,449 customers generating over $10,000 in Cloud annualized recurring revenue (Cloud ARR), a 15% increase from the previous year.

    Performance Rankings

    TEAM maintains an ST score of 43 on our screener, with a bullish rating, reinforcing investor confidence in its long-term growth trajectory. For further insights into similar peer stocks within the Software-Application industry, visit our ST screener link.

  • High Roller (ROLR) Shares Rally In Extended Session, Driven By New Collaboration

    High Roller (ROLR) Shares Rally In Extended Session, Driven By New Collaboration

    High Roller Technologies, Inc. (NYSE: ROLR) had a sharp increase in its stock price, finishing the regular session at $4.83, up 6.62%. The stock price then increased by 5.59% after hours to $5.10. The announcement of a significant agreement that is anticipated to improve the company’s operational efficiency and market positioning is what caused the upward momentum.

    Strategic Partnership with Golden Whale

    Golden Whale, a top data science company that specializes in machine learning and predictive analytics, has announced a strategic partnership with High Roller Technologies, a major operator of the High Roller and Fruta online gambling brands.

    The collaboration, which is scheduled to begin in late Q4 2024, is to use cutting-edge AI-driven models to maximize player acquisition and retention tactics. ROLR aims to strengthen its income streams and improve player engagement strategies by incorporating Golden Whale’s experience, reaffirming its dedication to providing a cutting-edge online gaming experience.

    It is anticipated that the partnership would improve resource allocation, streamline internal procedures, and fortify High Roller’s position in the market. Both firms’ executives have voiced excitement about the partnership, highlighting its potential to spur long-term growth and open up new revenue streams in the cutthroat online gaming industry.

    Recognition at International Gaming Awards 2025

    In addition to its recent achievements, High Roller Technologies won the International Gaming Awards 2025’s coveted Affiliate Marketing Campaign of the Year title. The event honored ROLR’s data-driven marketing strategy on January 19, 2025, at the Intercontinental Hotel in Barcelona, Spain.Sven Kaltenegger, the company’s chief marketing officer, collected the award on the company’s behalf, highlighting its dedication to affiliate partnership excellence.

    Dedication to Sustainable Development

    Using data-driven insights to maximize affiliate and operator connections, High Roller’s marketing methods place a high priority on mutual success and long-term collaborations. The company’s goal is to maintain sustainable growth while improving its market presence via constant innovation and open communication.

    The recent industry recognition and strategic collaboration with Golden Whale position ROLR for continued success in the evolving online gaming landscape.

  • Cipher Mining (CIFR) Jumps In Extended Session As SoftBank Becomes A Key Investor

    Cipher Mining (CIFR) Jumps In Extended Session As SoftBank Becomes A Key Investor

    Cipher Mining Inc. (NASDAQ: CIFR) shares had a sharp rise during Thursday’s extended trading session, closing at $5.72 after climbing 21.70%. One of the most potent investment holding companies in the world, SoftBank Group, reported a significant investment in the company, which caused this jump.

    Boosting Innovation and Strategic Growth

    SoftBank has contributed $50 million in Private Investment in Public Equity (PIPE) to Cipher’s high-performance computing, or HPC, data center construction. The investment makes SoftBank a major CIFR investor at a critical juncture in the expansion of the company.

    Cipher’s industrial-scale data center projects have earned company notoriety, and SoftBank’s dedication to developing artificial intelligence and technology complements Cipher’s long-term goals. It is anticipated that this strategic support would strengthen CIFR’s position as a leader in the HPC data center industry and hasten its expansion.

    Strength in Finance and Improvements in Operations

    Cipher demonstrates strong financial valuation within the Financial – Capital Market industry, as indicated on the ST screener. Investors can explore similar-rated peer stocks through our ST screener link.

    In December, Cipher’s operations and construction teams completed an extensive upgrade to the mining fleet at its Odessa facility while making notable progress on the Black Pearl data center development. The Odessa upgrade has positioned CIFR with an impressive 13.5 exahashes per second (EH/s) of self-mining capacity, utilizing one of the most efficient mining fleets in the industry at approximately 18.9 joules per terahash (J/TH).

    Resilient Bitcoin Production and Treasury Management

    Leveraging cutting-edge data center technologies, Cipher managed to draw power from the grid even when its power provider exercised curtailment options. Despite nearly 20% of annual curtailment hours being utilized in December, CIFR successfully continued mining operations during approximately 80 otherwise curtailed hours.

    The company reported producing 2,341 BTC during the month and, as part of its treasury management strategy, sold 271 BTC, concluding December with a Bitcoin balance of 13,442 BTC.

  • Tectonic Therapeutic (TECX) Stock Soars On Positive Clinical Trial Update

    Tectonic Therapeutic (TECX) Stock Soars On Positive Clinical Trial Update

    The revelation of favorable interim data from a crucial clinical trial is causing Tectonic Therapeutics, Inc. (NASDAQ: TECX) shares soared 114.89% as of the last check to $55.27. Consequently, the market value of the firm has surpassed $800 million. To see more biotechnology businesses with market capitalizations over $1 billion, visit our ST screener link.

    Positive Clinical Trial Results

    Tectonic Therapeutics (TECX) reported encouraging results from a Phase 1b clinical trial that looked at its main product candidate, TX45. It is a long-acting Fc-relaxin fusion protein, which showed significant improvements in key clinical metrics.

    Patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction or PH-HFpEF showed significant improvements in pulmonary hemodynamics and left ventricular function after receiving a single intravenous dose of TX45. There were no serious side effects observed, and the medication was well tolerated overall.

    Key Clinical Findings and Implications

    Among the trial’s broader patient group, TX45 achieved a 17.9% reduction in pulmonary capillary wedge pressure (PCWP), a known marker of exercise capacity, morbidity, and mortality in heart failure patients. For a subpopulation with combined pre- and post-capillary pulmonary hypertension (CpcPH), TX45 delivered an impressive reduction of over 30% in pulmonary vascular resistance (PVR).

    This is a critical finding, as both PVR and PCWP are linked to exercise capacity and survival rates in these patients. The trial’s endpoints align closely with those of Tectonic Therapeutics’ ongoing APEX Phase 2 study, with results expected in 2026.

    Looking Ahead: Advancing TX45 Development

    The interim data are seen as a strong advancement in Tectonic Therapeutics’ TX45 clinical program, meeting or exceeding the company’s prespecified objectives. These results offer hope for patients suffering from PH-HFpEF, a condition with limited treatment options and high mortality.

    The encouraging data supports TECX’s continued efforts for the development of TX45, which aims to address the underlying causes of the disease and improve patient outcomes in this challenging population.

  • Alterity (ATHE) Sees Major Stock Rally After Clinical Success

    Alterity (ATHE) Sees Major Stock Rally After Clinical Success

    Following the release of encouraging clinical trial data, Alterity Therapeutics Limited (NASDAQ: ATHE) stock value has significantly increased. ATHE shares have risen 47.42% to $4.29 as of the most recent market check.

    Alterity Unveiled Breakthrough in MSA Treatment

    The ATH434-201 Phase 2 clinical trial, a randomized, double-blind, placebo-controlled study evaluating ATH434 in individuals with early-stage multiple system atrophy (MSA), provided Alterity (ATHE) with promising topline findings.

    A key instrument for assessing disability in daily activities impacted by MSA, the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, was found to be significantly improved by ATH434 in both clinical and statistical analyses. After 52 weeks, the drug postponed clinical development by 29% at the 75 mg level and 48% at the 50 mg dose as compared to a placebo.

    Biomarker and MRI Evidence Support Drug Efficacy

    In this uncommon, fast-progressing illness, ATH434 has shown a notable slowdown of clinical development along with an exceptional safety profile. These findings suggest that ATH434’s targeted iron engagement may really have a disease-modifying impact, considering there are currently no authorized medications that delay the course of MSA.

    ATHE On Pathway Toward FDA Engagement

    With no currently approved treatments capable of slowing MSA progression, these findings suggest that ATH434 may offer a transformative disease-modifying effect. Alterity Therapeutics has confirmed its intent to engage with the U.S. Food and Drug Administration (FDA) to accelerate development plans based on these promising results.

    This breakthrough has implications for developing disease-modifying treatments for both orphan diseases like MSA and major neurodegenerative disorders, offering new hope for patients facing these debilitating conditions.

    Market Performance and Analyst Ratings

    Following these promising clinical trial results, Alterity Therapeutics has garnered increased attention from analysts and investors. ATHE stock has an ST score of 43 on our screener, with analysts assigning a Strong Buy rating. Investors seeking insights into comparable biotechnology stocks can explore our screener link for further analysis.

  • Calix (CALX) Sees Pre-Hour Trading Boost On Strong Results

    Calix (CALX) Sees Pre-Hour Trading Boost On Strong Results

    Calix, Inc. (NYSE: CALX) shares are trading 9.03% up at $40.20 as of the last check during today’s pre-market session. The increase comes after the release of its fourth-quarter earnings report, which showed continued revenue growth and operational efficiency.

    Strong Fourth-Quarter Performance

    Calix reported revenue of $206.1 million, up 2.6% from the previous quarter, marking the second consecutive quarter of sequential revenue growth, highlighting the company’s strong performance in its managed services, cloud, and appliance-based platform model.

    Calix also continued its run of double-digit free cash flow for the seventh consecutive quarter, extending its run of positive free cash flow to 18 consecutive quarters, further solidifying its strong financial position. Record Gross Margin and Growing Market Presence

    The company achieved record gross margins once again, bolstered by the success of its broadband experience provider (BEP) customers. These clients have continued to expand their subscriber bases through Calix’s platform, cloud, and managed services, offering distinctive broadband experiences.

    Consequently, Calix reported a 34% year-over-year and 10% quarter-over-quarter increase in remaining performance obligations (RPOs), climbing to $325.8 million. Calix also welcomed 18 new broadband service providers during the quarter embarking on their subscriber experience journey.

    Additionally, CALX saw a rise in service adoption, adding 21 new platform deployments, 15 new cloud deployments, and 32 new managed service implementations. This expansion highlights the company’s ability to provide sustainable, profitable growth opportunities for broadband providers transitioning into experience-driven service models.

    Capitalizing on Industry Disruption

    Calix remains in the early stages of a transformative shift within the broadband industry. Its BEP customers continue to thrive amid market disruptions, leveraging Calix’s business model to differentiate their offerings and attract consumers, businesses, and municipal clients.

    As legacy network operators grapple with increasing commoditization, margin compression, and slowing growth, Calix aims to accelerate its expansion by converting more operators into broadband experience providers.

    Stock Performance and Industry Standing

    Together with the positive earnings report, CALX currently holds an ST score of 53, indicating a bearish stance within the Software-Application industry. Investors seeking stocks with stronger short-term performance can explore peer companies with higher ST scores with Bullish performance using our screener link.